Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IRAK1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IRAK1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/IRAK1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IRAK1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/IRAK1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/IRAK1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IRAK1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003629425 | Thyroid | ATC | cellular response to decreased oxygen levels | 85/6293 | 161/18723 | 3.86e-07 | 5.65e-06 | 85 |
GO:003434015 | Thyroid | ATC | response to type I interferon | 38/6293 | 58/18723 | 6.67e-07 | 9.13e-06 | 38 |
GO:003109826 | Thyroid | ATC | stress-activated protein kinase signaling cascade | 120/6293 | 247/18723 | 7.06e-07 | 9.46e-06 | 120 |
GO:0045785210 | Thyroid | ATC | positive regulation of cell adhesion | 194/6293 | 437/18723 | 1.40e-06 | 1.75e-05 | 194 |
GO:005140326 | Thyroid | ATC | stress-activated MAPK cascade | 115/6293 | 239/18723 | 2.17e-06 | 2.58e-05 | 115 |
GO:003460533 | Thyroid | ATC | cellular response to heat | 42/6293 | 69/18723 | 3.16e-06 | 3.59e-05 | 42 |
GO:007145624 | Thyroid | ATC | cellular response to hypoxia | 78/6293 | 151/18723 | 3.44e-06 | 3.86e-05 | 78 |
GO:000940832 | Thyroid | ATC | response to heat | 60/6293 | 110/18723 | 4.89e-06 | 5.32e-05 | 60 |
GO:007135714 | Thyroid | ATC | cellular response to type I interferon | 33/6293 | 52/18723 | 1.01e-05 | 1.00e-04 | 33 |
GO:006033714 | Thyroid | ATC | type I interferon signaling pathway | 32/6293 | 50/18723 | 1.06e-05 | 1.05e-04 | 32 |
GO:005109022 | Thyroid | ATC | regulation of DNA-binding transcription factor activity | 190/6293 | 440/18723 | 1.49e-05 | 1.39e-04 | 190 |
GO:007190215 | Thyroid | ATC | positive regulation of protein serine/threonine kinase activity | 96/6293 | 200/18723 | 1.63e-05 | 1.51e-04 | 96 |
GO:003248113 | Thyroid | ATC | positive regulation of type I interferon production | 35/6293 | 58/18723 | 2.70e-05 | 2.30e-04 | 35 |
GO:000926632 | Thyroid | ATC | response to temperature stimulus | 83/6293 | 178/18723 | 2.03e-04 | 1.35e-03 | 83 |
GO:003214711 | Thyroid | ATC | activation of protein kinase activity | 65/6293 | 134/18723 | 2.44e-04 | 1.57e-03 | 65 |
GO:004340513 | Thyroid | ATC | regulation of MAP kinase activity | 82/6293 | 177/18723 | 2.87e-04 | 1.83e-03 | 82 |
GO:000222114 | Thyroid | ATC | pattern recognition receptor signaling pathway | 80/6293 | 172/18723 | 2.89e-04 | 1.84e-03 | 80 |
GO:006075912 | Thyroid | ATC | regulation of response to cytokine stimulus | 76/6293 | 162/18723 | 2.92e-04 | 1.85e-03 | 76 |
GO:000195912 | Thyroid | ATC | regulation of cytokine-mediated signaling pathway | 71/6293 | 150/18723 | 3.28e-04 | 2.04e-03 | 71 |
GO:190122421 | Thyroid | ATC | positive regulation of NIK/NF-kappaB signaling | 37/6293 | 69/18723 | 4.80e-04 | 2.81e-03 | 37 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051711 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa051321 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa051301 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa051351 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa054171 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa051712 | Colorectum | SER | Coronavirus disease - COVID-19 | 98/1580 | 232/8465 | 3.33e-17 | 8.50e-16 | 6.17e-16 | 98 |
hsa051322 | Colorectum | SER | Salmonella infection | 77/1580 | 249/8465 | 1.56e-06 | 2.35e-05 | 1.71e-05 | 77 |
hsa051302 | Colorectum | SER | Pathogenic Escherichia coli infection | 60/1580 | 197/8465 | 3.63e-05 | 4.31e-04 | 3.13e-04 | 60 |
hsa051352 | Colorectum | SER | Yersinia infection | 43/1580 | 137/8465 | 2.15e-04 | 2.10e-03 | 1.52e-03 | 43 |
hsa051702 | Colorectum | SER | Human immunodeficiency virus 1 infection | 58/1580 | 212/8465 | 1.08e-03 | 8.56e-03 | 6.21e-03 | 58 |
hsa047222 | Colorectum | SER | Neurotrophin signaling pathway | 35/1580 | 119/8465 | 2.80e-03 | 2.02e-02 | 1.47e-02 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IRAK1 | SNV | Missense_Mutation | | c.1748A>G | p.Asn583Ser | p.N583S | P51617 | protein_coding | tolerated(0.07) | probably_damaging(0.996) | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
IRAK1 | SNV | Missense_Mutation | | c.1263N>C | p.Gln421His | p.Q421H | P51617 | protein_coding | deleterious(0.02) | probably_damaging(0.925) | TCGA-AR-A2LE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | PD |
IRAK1 | SNV | Missense_Mutation | rs782334259 | c.1984N>G | p.Ile662Val | p.I662V | P51617 | protein_coding | tolerated(0.1) | probably_damaging(0.984) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR |
IRAK1 | insertion | In_Frame_Ins | novel | c.464_465insCCCCTCTGTGAGATTTCCCGGGGC | p.Pro156_Glu157insSerValArgPheProGlyAlaPro | p.P156_E157insSVRFPGAP | P51617 | protein_coding | | | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK1 | SNV | Missense_Mutation | novel | c.335N>A | p.Gly112Asp | p.G112D | P51617 | protein_coding | tolerated(0.16) | benign(0.006) | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
IRAK1 | SNV | Missense_Mutation | novel | c.1555N>C | p.Glu519Gln | p.E519Q | P51617 | protein_coding | tolerated(0.15) | probably_damaging(0.998) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
IRAK1 | insertion | Nonsense_Mutation | novel | c.333_334insTAAA | p.Gly112Ter | p.G112* | P51617 | protein_coding | | | TCGA-DS-A1OA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
IRAK1 | SNV | Missense_Mutation | novel | c.505N>G | p.Pro169Ala | p.P169A | P51617 | protein_coding | deleterious(0.01) | benign(0.165) | TCGA-A6-2683-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | irinotecan | PD |
IRAK1 | SNV | Missense_Mutation | | c.1936N>A | p.Ala646Thr | p.A646T | P51617 | protein_coding | tolerated(0.6) | benign(0.015) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
IRAK1 | SNV | Missense_Mutation | | c.1141A>T | p.Thr381Ser | p.T381S | P51617 | protein_coding | deleterious(0.01) | possibly_damaging(0.874) | TCGA-CK-4947-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Other, specify in notes | folinic | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | PF-562271 | PF-00562271 | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565765 | | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | GEFITINIB | GEFITINIB | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | GW441756X | GW441756X | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | LINIFANIB | LINIFANIB | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 249565764 | | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 385612233 | | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | TAMATINIB | R-406 | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | | RG-1530 | RG-1530 | |
3654 | IRAK1 | DRUGGABLE GENOME, KINASE, SERINE THREONINE KINASE, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 348353615 | | |